Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 424.93% from the stock’s previous close.

Curis Stock Down 3.8 %

CRIS opened at $3.81 on Tuesday. The firm has a market capitalization of $32.26 million, a P/E ratio of -0.49 and a beta of 3.35. The stock has a fifty day moving average of $4.52 and a 200-day moving average of $5.80. Curis has a 12-month low of $3.51 and a 12-month high of $17.49.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently bought and sold shares of the business. Focused Wealth Management Inc lifted its position in shares of Curis by 63.1% in the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Curis by 795.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 96,256 shares during the period. Finally, Vanguard Group Inc. lifted its position in Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after buying an additional 10,097 shares in the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.